Compass Therapeutics, Inc. (CMPX)
(Real Time Quote from BATS)
$2.78 USD
-0.13 (-4.47%)
Updated Aug 7, 2025 12:42 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CMPX 2.78 -0.13(-4.47%)
Will CMPX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMPX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMPX
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock?
Compass Therapeutics Stock Skyrockets 108% in a Month: Here's Why
CMPX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Compass Therapeutics, Inc. (CMPX) Stock Outpacing Its Medical Peers This Year?
Down -23.46% in 4 Weeks, Here's Why You Should You Buy the Dip in Compass Therapeutics, Inc. (CMPX)
What Makes Compass Therapeutics, Inc. (CMPX) a New Buy Stock
Other News for CMPX
Compass Therapeutics (CMPX) Receives Outperform Rating from Raymond James | CMPX Stock News
Compass Therapeutics resumed with an Outperform at Raymond James
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer
Compass Therapeutics (CMPX) Receives a Buy from Piper Sandler
Compass Therapeutics management to meet virtually with Piper Sandler